Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.
Auteurs : Razis E, Escudero MJ, Palmieri C, Mueller V, Bartsch R, Rossi G, Gampenrieder SP, Kolberg HC, Zdenkowski N, Pavic M, Connolly RM, Rosset L, Arcuri J, Tesch H, Vallejos C, Retamales J, Musolino A, Del Mastro L, Christodoulou C, Aebi S, Paluch-Shimon S, Gupta S, Ohno S, Macpherson I, Ekholm M, Zaman K, Vidal M, Chakiba C, Fumagalli D, Thulin A, Witzel I, Kotecki N, Gil-Gil M, Linderholm B Jaar : 2022 Journal : ESMO Open
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
Auteurs : Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E Jaar : 2022 Journal : Liver Cancer
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.
Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E Jaar : 2022 Journal : ESMO Open
Molecular oncology: what is needed to speed access to innovative therapies in clinical research?
Auteurs : Gourari K, Awada A, Kotecki N Jaar : 2022 Journal : Curr Opin Oncol
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Auteurs : Kotecki N, Vuagnat P, ONeil BH, Jalal S, Rottey S, Prenen H, Benhadji KA, Xia M, Szpurka AM, Saha A, Wallin J, Suriyapperuma S, Galvao VR, Geeganage S, Doman TN, Gandhi L, Xu X, Bendell J Jaar : 2021 Journal : J Immunother